Orphan Medical Vice President of Regulatory Affairs Receives FDA Citation

June 11, 1999.

Contact: John Bullion of Orphan Medical, Inc. 952-513-6900 Orphan Medical Vice President of Regulatory Affairs Receives FDA Citation MINNEAPOLIS, June 11, 1999 – Orphan Medical, Inc. (Nasdaq: ORPH) announced today that Vice President of Regulatory Affairs Dayton T. Reardan, Ph.D., RAC, was selected to receive the Food and Drug Administration’s (FDA) Commissioner’s Special Citation. The citation is to recognize his outstanding commitment in the development of products for patients with rare diseases and his assistance to the FDA. The Commissioner’s Special Citation is granted solely at the discretion of the commissioner to recognize an individual for their contribution to the mission of the Food and Drug Administration which is to protect the public health, as directed by the Federal Food, Drug, and Cosmetic Act, and to administer the statutory framework of this law by providing new and better products. The award was presented to Dr. Reardan at the FDA Awards Ceremony on June 11, 1999. "This citation is a tribute to what we strive to achieve at Orphan Medical," said John H. Bullion, Orphan Medical’s Chief Executive Officer. "Dr. Reardan’s commitment and leadership have been key in the success we have had as a company bringing five products to market in our short history and working with the FDA to move forward our development of Xyrem™ (sodium oxybate) oral solution which is currently being investigated through an FDA approved Treatment IND for the treatment of cataplexy, a debilitating symptom of narcolepsy." Dr. Reardan has been the Company’s Vice President of Regulatory Affairs since May, 1995, and had been the Director of Regulatory Affairs since joining the Company in 1994. Prior to joining Orphan Medical he was the Director of Development at CV Therapeutics, 1993-1994, and held a variety of management positions at Xoma Corporation between 1984 and 1993, serving most recently as Director of Project Management. Orphan Medical, Inc. is dedicated to patients with inadequately treated or uncommon diseases. To that end, the Company acquires, develops, and markets products of high medical value for patients within selected strategic therapeutic market segments. Orphan Medical’s Internet Web Site address is http://www.orphan.com.